Current Issues in Bioavailability and Bioequivalence

When administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses, the rate and extent of absorption of the test drug does not show a significant difference from the rate and extent of absorption of the reference drug. Should the rate of absorption varies amongst products, it must be deliberate and stated in the proposed product label, and it must be clearly proved that it is not necessary for achieving effective body drug concentrations on chronic usage or that it is medically irrelevant for the drug. In practise, equivalence is defined as when key pharmacokinetic parameters required to determine the rate and scope of the test, as well as reference products, fall within a predetermined confidence interval. If a drug product is pharmaceutically comparable to the innovator product, meaning it has the same active ingredient, dosage form, strength, and method of administration, and is bioequivalent, the FDA determines it to be therapeutically equivalent. Therapeutically identical products can be used interchangeably. As a result, BE studies are viewed as surrogates for comparative clinical trials in order to determine therapeutic equivalence in terms of safety and efficacy between two pharmacological candidates.


  • Biotransformation
  • Physico-chemical factors
  • Energy dependent efflux transporters
  • CYP450 isozymes

Related Conference of Current Issues in Bioavailability and Bioequivalence

December 07-08, 2022

9th Asian Herbal and Traditional Medicine summit

Paris, France
December 07-08, 2022

14th World Congress on Personalized Medicine and Novel Therapy

Singapore City, Singapore
December 12-13, 2022

5th International Pharmacy and Pharmaceutical Conference

Dublin, Ireland
February 14-15, 2023

8th Pharmaceutical Chemistry Conference

Paris, France
February 20-21, 2023

20th Annual Meet on Pharmaceutical Sciences

Rome, Italy
March 10-11, 2023

Global Pharmaceutical and Pharma Industry Conference

Brussels, Belgium
March 13-14, 2023

33rd Annual European Pharma Congress

Frankfurt, Germany
March 27-28, 2023

16th Global Pharmacovigilance & Clinical Trials Summit

Vancouver, Canada
April 03-04, 2023

16th European Biosimilars Congress

Barcelona, Spain
April 25-26, 2023

4th Annual Congress on Antibiotics and Bacterial Infections

Amsterdam, Netherlands
May 07-08, 2023

Advanced-Materials 2023

Valencia, Spain
July 25-26, 2023

36th World Congress on Pharmacology

Amsterdam, Netherlands
August 11-12, 2023

38th World Congress on Pharmacology and Therapeutics

Singapore City, Singapore
August 28-29, 2023

23rd International Pharmaceutical Conference and Expo

Vancouver, Canada
September 06-30, -0001

16th World Drug Delivery Summit

London, UK
September 14-15, 2023

10th international conference on Physiotherapy

Bangkok, Thailand
September 27-28, 2023

3rd World Congress on Rare Diseases & Orphan Drugs

Amsterdam, Netherlands
September 27-28, 2023

8th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
October 02-03, 2023

18th World Conference on Pharmaceutical Chemistry

London, UK
October 09-10, 2023

20th International Conference on Pharmaceutical Chemistry

Barcelona, Spain
November 09-10, 2023

11th International Conference on Clinical Trials

London, UK
November 10-11, 2023

3rd World Biosimilars & Biologics Congress

Berlin, Germany

Current Issues in Bioavailability and Bioequivalence Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in